Grant: Catalyst Grant: Post Market Drug Safety and Effectiveness
University of British Columbia
$97,486.00
Pharmacogenetics of Warfarin Safety and Effectiveness in Children.
EF 2011-12
Résumé
Warfarin is a blood thinner that is widely used for the prevention and treatment of life-threatening blood clots in adults and children. Warfarin is a difficult drug to determine the safest dose for each patient because the required dose varies greatly between individuals. Patients who are prescribed warfarin are monitored closely to ensure the optimal drug level in the blood. A low level of warfarin puts patients at risk of forming blood clots, while a high level of warfarin increases the risk of serious bleeding. Genes have been identified in adult patients that significantly contribute to warfarin dose variation. The relevance of these findings in children, however, is not known. This project will explore the role of warfarin pharmacogenetic markers in children, with three key objectives: (1) to assess the importance of adult warfarin pharmacogenetic variants on warfarin response in children; (2) to investigate the contribution of warfarin pharmacogenetic variants to severe warfarin ADRs and extreme warfarin resistance in children; and (3) to explore the effects of warfarin pharmacogenetic patient genotypes on plasma warfarin concentrations in children receiving warfarin. The anticipated results of this study will provide important information about the potential benefits of genetic testing in children prior to starting warfarin therapy. Genetic testing will improve clinician estimations of optimal dosing for each individual patient, allow the early prediction of children who are at a high risk of experiencing adverse drug reactions from warfarin, and thus help minimize the dangers associated with warfarin therapy in children.
Programme
Catalyst Grant: Post Market Drug Safety and Effectiveness
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
244057
Name
Ross Colin J
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Genetics
Theme2
Biomedical
Prcname2
Catalyst Grant: Post Market Drug Safety and Effectiveness
Projecttitle
Pharmacogenetics of Warfarin Safety and Effectiveness in Children.
Programtype2
Operating Grants
Orgnameinp2
University of British Columbia
Cihramount2
$97,486
Cihrequipment2
$0
Programname2
Catalyst Grant: Post Market Drug Safety and Effectiveness
Keyworddelim
Adverse Drug Reaction; Drug Effectiveness; Drug Safety; Pediatrics; Pharmacogenetics; Warfarin
Abstract
Warfarin is a blood thinner that is widely used for the prevention and treatment of life-threatening blood clots in adults and children. Warfarin is a difficult drug to determine the safest dose for each patient because the required dose varies greatly between individuals. Patients who are prescribed warfarin are monitored closely to ensure the optimal drug level in the blood. A low level of warfarin puts patients at risk of forming blood clots, while a high level of warfarin increases the risk of serious bleeding. Genes have been identified in adult patients that significantly contribute to warfarin dose variation. The relevance of these findings in children, however, is not known. This project will explore the role of warfarin pharmacogenetic markers in children, with three key objectives: (1) to assess the importance of adult warfarin pharmacogenetic variants on warfarin response in children; (2) to investigate the contribution of warfarin pharmacogenetic variants to severe warfarin ADRs and extreme warfarin resistance in children; and (3) to explore the effects of warfarin pharmacogenetic patient genotypes on plasma warfarin concentrations in children receiving warfarin. The anticipated results of this study will provide important information about the potential benefits of genetic testing in children prior to starting warfarin therapy. Genetic testing will improve clinician estimations of optimal dosing for each individual patient, allow the early prediction of children who are at a high risk of experiencing adverse drug reactions from warfarin, and thus help minimize the dangers associated with warfarin therapy in children.
Competitiondate
201110
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ross, Colin J; Carleton, Bruce C
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $97,486~ $0~